bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on BLUE. Royal Bank of Canada reissued a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a research note on Friday, November 15th. Wells Fargo & Company cut their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and cut their price target for the stock from $60.00 to $10.00 in a report on Friday, November 15th. Barclays lifted their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, December 31st. Finally, Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $48.10.

bluebird bio Price Performance

Shares of BLUE opened at $3.75 on Wednesday. The firm has a market capitalization of $36.46 million, a PE ratio of -0.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a 1-year low of $3.56 and a 1-year high of $30.90. The company’s fifty day moving average price is $6.46 and its 200-day moving average price is $8.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC acquired a new stake in shares of bluebird bio during the 3rd quarter worth approximately $42,000. Captrust Financial Advisors boosted its stake in bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 77,293 shares in the last quarter. Barclays PLC boosted its stake in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 184,605 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of bluebird bio in the fourth quarter valued at $175,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.